Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Glenmark Pharmaceuticals
Research
Trispecific antibody one-ups Tecvayli in myeloma mouse study
At one dosage, ISB 2001 completely eradicated the tumors of all eight mice; Tecvayli, meanwhile, had no complete regressions.
Darren Incorvaia
Sep 17, 2024 3:38pm
Glenmark bags subcutaneous checkpoint inhibitor rights
Jan 25, 2024 9:30am
Intima snags Gilead's former Yescarta leader for cell Tx chops
Nov 10, 2021 10:10am
Novartis Oncology veterans reunite at Glenmark spinoff Ichnos
Feb 5, 2020 10:14am
Alessandro Riva to leave Gilead to lead Glenmark spinoff
Mar 6, 2019 9:43am
India’s Glenmark spins out NMEs into U.S. company
Feb 15, 2019 8:55am
